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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER599Mitochondria as a Therapeutic Target in Heart FailureMarina Bayeva, Mihai Gheorghiade, Hossein Ardehali
The existing therapies for heart failure provide symptomatic relief, but are unable to reverse
molecular changes that occur in cardiomyocytes. The mechanisms of heart failure are complex
and multiple, but mitochondrial dysfunction appears to be an early and critical factor in the
development of this disease. This review by Bayeva and colleagues discusses 3 promising areas
for the development of heart failure therapies, including mitochondrial biogenesis,
mitochondrial oxidative stress, and mitochondrial iron handling.VIEWPOINT VIEWPOINT611Clinical Significance of Circulating TroponinRichard L. Popp
The “Third Universal Definition of Myocardial Infarction” states, “Myocardial injury is
detected when blood levels of sensitive and specific biomarkers such as cTn [cardiac troponin]
are increased.” New generations of high-sensitivity assays find circulating cTn in virtually all
subjects and higher levels of cTn are predictive of future heart failure. Popp explores the
mechanisms of cTn release and proposes that in at least some cases, initial myocardial damage
may lead to anti-cTn antibodies that participate in ongoing myocardial damage that
eventually results in heart failure.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY615Intracoronary Enalaprilat May Reduce Microvascular Damage During PCIFabio Mangiacapra, Aaron J. Peace, Luigi Di Serafino, Stylianos A. Pyxaras, Jozef Bartunek, Eric Wyffels,
Guy R. Heyndrickx, William Wijns, Bernard De Bruyne, Emanuele Barbato
The ProMicro study investigated the effect of intracoronary enalaprilat on coronary
microvascular function and peri-procedural myocardial injury in patients with stable angina
undergoing percutaneous coronary intervention (PCI). A total of 40 patients were randomly
assigned to either an intracoronary bolus of enalaprilat or placebo immediately prior to PCI.
Infusion of enalaprilat resulted into a significant reduction in the index of microvascular
resistance (IMR), while placebo treated patients had a post-procedural increase in IMR.
Enaliprilat pre-treated patients were less likely to have a peri-procedural increase in troponin.
This small study suggests the need for a larger one to confirm the clinical utility of
intracoronary enalaprilat prior to PCI.(continued on page A-28)
FEBRUARY 12, 2013 (continued) A-28CORONARY ARTERY DISEASE622Cardiac Risks of Depression Linked to Behavioral MechanismsSiqin Ye, Paul Muntner, Daichi Shimbo, Suzanne E. Judd, Joshua Richman, Karina W. Davidson,
Monika M. Safford
Ye and colleagues sought to determine whether behavioral mechanisms explain the association
between depressive symptoms and myocardial infarction (MI) or death in individuals with
coronary heart disease (CHD). There was a higher risk of subsequent MI or death in subjects
with elevated depressive symptoms after adjusting for demographics (hazard ratio [HR]:
1.41), but it was no longer significant after adjusting for behavioral mechanisms (HR: 1.14).
Of the 4 behavioral mechanisms (alcohol use, smoking, physical inactivity, and medication
nonadherence), smoking and physical inactivity had the biggest explanatory roles. These
findings suggest potential roles for behavioral interventions targeting smoking and physical
inactivity in patients with CHD and comorbid depression.Editorial Comment: James A. Blumenthal, p. 631HEART FAILURE635Risk Factors for Hospitalization Among Older Persons Newly Diagnosed With HFSarwat I. Chaudhry, Gail McAvay, Shu Chen, Heather Whitson, Anne B. Newman, Harlan M. Krumholz,
Thomas M. Gill
Chaudhry and colleagues used data from the Cardiovascular Health Study to identify risk
factors for all-cause hospitalizations among older persons following heart failure (HF)
diagnosis, and to determine whether geriatric conditions would emerge as independent risk
factors. The mean rate of hospitalization after a HF diagnosis was 7.9 per 10 person-years.
Independent risk factors for hospitalization included depressed ejection fraction, NYHA
classes III or IV, diabetes mellitus, chronic kidney disease, weak grip strength, slow gait
speed, and depression. These results shows that common geriatric conditions such as weak
grip strength, slow gait speed, and depression increase the risk of hospitalization for patients
with HF to a similar degree as other more recognized risk factors.Editorial Comment: Philip B. Adamson, p. 643HEART RYHTHM DISORDERS646Meta-Analysis Links ERP to Higher Risk of Arrhythmic DeathSu-Hua Wu, Xiao-Xiong Lin, Yun-Jiu Cheng, Can-Can Qiang, Jing Zhang
Wu and colleagues studied the risks associated with early repolarization pattern (ERP) on
resting electrocardiogram by performing a meta-analysis. ERP was defined as an elevation
0.1mV of the QRS-ST junction (J-point) in inferior and/or lateral leads. A total of 9
studies were included in the meta-analysis. The relative risk of ERP were 1.70 (p  0.003)
for arrhythmia death, 0.78 (p  0.63) for cardiac death, and 1.06 (p  0.57) for all-cause
death. These results confirm a link between ERP and arrhythmia causing death, but further
study is needed to clarify which subgroups of subjects with ERP are at higher risk and the
lack of an increase in cardiac or all-cause death is reassuring.(continued on page A-29)
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651o Significant Difference in Embolic Outcomes
With Temporary Discontinuation of Warfarin or RivaroxabanManesh R. Patel, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Zhongxin Zhang,
Surya Mohanty, Daniel E. Singer, Werner Hacke, Günter Breithardt, Jonathan L. Halperin,
Graeme J. Hankey, Richard C. Becker, Christopher C. Nessel, Scott D. Berkowitz, Robert M. Califf,
Keith A. A. Fox, Kenneth W. Mahaffey
There are ongoing concerns about a possible prothombotic state early after discontinuation of
rivaroxaban. Patel and colleagues performed a post-hoc analysis of data from ROCKET AF
regarding the risk of stroke or noncentral nervous system (CNS) embolism within 30 days
after temporary interruption of study drug, which was either warfarin or rivaroxaban. Stroke
and non-CNS embolism occurred at similar rates after temporary interruptions, and after
early permanent discontinuation. Patients transitioning to open-label therapy, usually warfarin
at end of study, had a higher rate of strokes if they were previously taking rivaroxaban, which
likely reflects the longer time it took to achieve a therapeutic international normalized ratio.
These results do not suggest a prothrombotic effect of discontinuation of rivaroxaban, but
highlight the risk of interrupting therapeutic anticoagulation for this group of patients.Editorial Comment: Matthew R. Reynolds, p. 659CARDIAC IMAGING
661TCA Improves Risk Stratification in Patients
Undergoing Intermediate-Risk Noncardiac SurgeryJong-Hwa Ahn, Jeong Rang Park, Ji Hyun Min, Ju-Tae Sohn, Seok-Jae Hwang, Yongwhi Park,
Jin-Sin Koh, Young-Hoon Jeong, Choong Hwan Kwak, Jin-Yong Hwang
Ahn and colleagues evaluated whether coronary artery calcium scores (CACS) and the degree
of stenosis as measured with computed tomography coronary angiography (CTCA) predict
post-operative cardiovascular events in patients undergoing intermediate-risk noncardiac
surgery. A total of 239 patients underwent CTCA prior to surgery, and 8% had post-
operative cardiac events. Predictive variables for cardiac events were the revised cardiac risk
index (RCRI), CACS, the presence of significant coronary artery stenosis (diameter stenosis
50%), and multivessel coronary artery disease. When comparing receiver-operating curves
(ROC) of combination models, RCRI  high CACS, RCRI  multivessel disease, and
RCRI  high CACS  multivessel disease were significantly more predictive of post-
perative cardiovascular events than RCRI alone suggesting multiple methods whereby
TCA can improve noncardiac surgery risk stratification.
ditorial Comment: Richard A. Lange, p. 669(continued on page A-30)
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Julika Schön, Hauke Paarmann, Michael Petersen, Thorsten Hanke
Growth-differentiation factor-15 (GDF-15) is expressed in most tissues, including
myocardium, with increased expression of this cytokine induced by myocardial stretch, volume
overload, oxidative stress, and ischemia-reperfusion. Heringlake and colleagues studied its
utility for risk stratification in patients undergoing cardiac surgery. A total of 1,458
consecutive patients were prospectively studied with pre-operative biomarker measurements.
Median GDF-15 levels were significantly lower in 30-day survivors than in 30-day
nonsurvivors. Further analysis showed that GDF-15 added prognotic information to the
additive Euroscore with a net-reclassification-improvement of 41%. Pre-operative plasma
GDF-15 level is an independent predictor of post-operative mortality in cardiac surgery
patients.Editorial Comment: Richard A. Lange, p. 682
